KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Operating Expenses (2017 - 2025)

Rigel Pharmaceuticals (RIGL) has 13 years of Other Operating Expenses data on record, last reported at $6.0 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 2.87% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $19.6 million, up 5.22%, while the annual FY2025 figure was $19.6 million, 5.22% up from the prior year.
  • Other Operating Expenses reached $6.0 million in Q4 2025 per RIGL's latest filing, up from $4.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $14.5 million in Q4 2022 and bottomed at $121000.0 in Q1 2022.
  • Average Other Operating Expenses over 5 years is $3.3 million, with a median of $2.4 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 1148.6% in 2021, then tumbled 73.91% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $4.0 million in 2021, then skyrocketed by 262.45% to $14.5 million in 2022, then plummeted by 73.91% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then increased by 2.87% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $6.0 million in Q4 2025, $4.8 million in Q3 2025, and $4.5 million in Q2 2025.